Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. [electronic resource]
Producer: 20061218Description: 5201-6 p. digitalISSN:- 1527-7755
- Adenocarcinoma -- drug therapy
- Adult
- Aged
- Angiogenesis Inhibitors -- administration & dosage
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Bevacizumab
- Camptothecin -- administration & dosage
- Cisplatin -- administration & dosage
- Disease Progression
- Disease-Free Survival
- Esophageal Neoplasms -- drug therapy
- Esophagogastric Junction
- Female
- Humans
- Irinotecan
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Stomach Neoplasms -- drug therapy
- Survival Analysis
- Treatment Outcome
- Vascular Endothelial Growth Factor A -- drug effects
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.